Trial Profile
A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jun 2021
Price :
$35
*
At a glance
- Drugs Tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms UPLIFT
- Sponsors Boehringer Ingelheim
- 19 May 2021 Results of pooled analysis from six studies (TONADO 1-2, DYNAGITO, WISDOM, UPLIFT and TIOSPIR) comparing the time to all-cause mortality with LAMA/LABA/ICS versus LAMA+LABA in a population of patients with predominantly moderate-to-severe COPD and a predominantly lower exacerbation risk, presented at the 117th International Conference of the American Thoracic Society.
- 23 May 2018 Results of post- hoc analysis assessing the association of a composite endpoint of clinically important deterioration (CID) with mortality, in patients with moderate-to-very-severe COPD in the UPLIFT trial presented at the 114th International Conference of the American Thoracic Society
- 24 May 2017 Results of post hoc analysis evaluating time-to-event analysis, presented at the 113th International Conference of the American Thoracic Society.